How can we use technology and increasing volumes of data to change the future of human health and healthcare as we move forward into 2023 and beyond? In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Bob Zambon, VP, Solution Architecture Group, Syneos Health, to discuss how increasing numbers of varying health data − medical data, clinical data, interaction data, program data – will affect a vastly privacy forward industry.Listen to the podcast to find out how data will impact the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field ForceFind more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: The Data Effect

How will a new field for the field force keep the doors open for customer communication while considering differences in culture, therapy, product lifecycle stage and healthcare professional preference?In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Ewan Cuthbertson, SVP, European Deployment Solutions, Syneos Health, to discuss how the field force is reemerging after a global pandemic and how it will impact the healthcare industry.Listen to the podcast to find out what a new field for the field force means for the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeFind more of our content on Digital Medicine and MedTech topics. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: A New Field for the Field Force

How will Digital transformation continue to impact the healthcare industry and help drive automation, efficiencies, quality and other changes to how we engage and operate in the future?In this episode of the limited Trend Talks series, Leigh Householder, Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Skye Hodson, PhD, Senior Director, Product Solutions & Asset Team, Syneos One, to discuss how various aspects of digital transformation continue to impact the healthcare industry.Listen to the podcast to find out what the future holds for healthcare and digital transformation. Learn more about 2023 Health Trends here.More Episodes int he 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for Purpose Find more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: Digital Transformation: Start, Stall, Restart

Last year the FDA approved the first gene therapy for hemophilia B. This year, the first gene therapy may be approved in the US for hemophilia A. What does the gene therapy revolution mean for patients, payers, and pharma? Ankita Chowdhury, Senior Engagement Manager, Commercial Advisory at Syneos Health®, joins the podcast to discuss the landscape of recent hemophilia gene therapy approvals, the state of upcoming additional therapies to market, and key considerations for developers to address in order to optimize access, pricing and reimbursement for patients impacted by this rare disease. For more of our insights on rare disease and gene therapies, check out:The Importance of the Right Go-to-Market in Cell Therapy CommercializationWEBINAR: Early Integrated Evidence Strategy for Cell & Gene TherapiesExploring an Expedited Regulatory Pathway for Cell and Gene TherapiesSuccess Factors for Commercializing Cell and Gene TherapiesSyneos Health Podcast: The Value of Registries NOTE: At the time of recording, Biomarin’s hemophilia A product was expected to receive FDA approval in March of this year. Since then, news broke that FDA review will be delayed until June.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Gene Therapy for Hemophilia

The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies?Dennis Kim, Senior Engagement Manager and Em Coriale, Director in the Value & Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.   For additional insights on the Inflation Reduction Act from our Reputation & Risk Management team, visit our blog.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The Inflation Reduction Act

How will Artificial Intelligence continue to impact the healthcare industry and its potential to introduce new technologies, enabling a shift from promise to performance?  In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Andrew Barron, SVP of Global Site Start Up & Regulatory, to discuss. Listen to the podcast here or watch the video to find out what they are thinking about ChatGPT, the next industrial revolution and more.Learn more about 2023 Health Trends here. And be sure to check out Leigh’s kick-off episode of the podcast series, as well as her recent interview with patient advocate James Ian.Find more of our content on site and patient engagement and regulatory topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: AI: Finally Fit for Purpose

 In this episode of the limited Trend Talks series, Leigh Householder Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with James Ian , a Musician and Actor who lives with Spinal Muscular Atrophy Type Three—a rare neuromuscular disease that attacks the neurons that control all the voluntary muscles in the body. James is a passionate advocate for disability inclusion, particularly in the arts and entertainment industry, and here they discuss representation of disabilities through authentic, intentional and purpose-driven advocacy in media and technology.  Listen to the podcast here or watch the video to learn what’s changed, what’s changing and what matters most right now. Learn more about 2023 Health Trends here. And be sure to check out Leigh’s kick-off episode of the podcast series (November 29—2023 Health Trends: Personally, Purposefully Building What’s Next).Find more of our content on rare disease and patient voice topics. Follow James Ian on Instagram @jamesianmusic  Leigh Householder is the EVP/Managing Director, Technology & Data at Syneos Health.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: AgeTech with Musician, Actor and Patient Advocate James Ian

This new podcast mini-series features interviews with industry leaders, focusing on hot topics within Regulatory Operations (Reg Ops).Reg Ops is evolving in response to a rapidly changing regulatory landscape as well as the industry’s focus on achieving operational efficiency and excellence. Technological innovations such as advancements in Regulatory Information Management (RIM) capabilities are accelerating Reg Ops in their transition from traditional operational roles to more strategically focused roles, including a shift toward Delivery Excellence. Organizations must adapt to the evolution of Reg Ops, including rethinking their approach to attracting and retaining talent, to remain competitive and at the forefront of innovation.In this episode, Reg Ops Edition host Caroline Masterman-Smith is joined by Matt Neal, Senior Director, Global Regulatory Affairs Operations at Atara Biotherapeutics; Stuart Goodall, Vice President of Regulatory Services Delivery at Syneos Health; and Hannah Riley, Engagement Manager within R&D Advisory at Syneos Health to discuss how the regulatory world has moved from truckloads of paper to electronic processes; how that, in turn, has changed the skillsets required for the Reg Ops function; and how companies need to think and act differently in order to attract and retain the talent they need.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  Be sure to read the white paper discussed in this episode: Attracting and Retaining Talent in the Age of Evolution for Regulatory OperationsIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Reg Ops Edition: Attracting and Retaining Talent

It’s a volatile time for biopharma, and a unique juncture in our industry’s history. War in Ukraine, a bearish market and supply chain chaos are just a few of the factors that kept much of the industry away from the table. Entering 2023, the investment and dealmaking panorama remains a puzzle. Despite worries and uncertainties, there are hints that dealmaking intensity may be poised for a rebound after a year of inertia that mirrored the slump in major biotech stock indexes. What lies ahead for dealmaking in the biopharmaceutical industry in 2023?Our 13th Dealmakers’ Intentions Survey attempts to answer this question, based on responses from more than 100 members of the biopharma community, most of them with executive-level influence on decision-making. This report, released recently at Biotech Showcase—an event co-located with the famous J.P. Morgan Healthcare Conference in San Francisco—captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking. Neel Patel, Executive Managing Director, Commercial Advisory Group at Syneos Health and lead author of the report, joins the podcast to discuss the industry’s first time back in person at J.P. Morgan in three years, as well as key findings from the survey.Read the latest Dealmakers’ Intentions report here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Life Sciences Dealmaking: Dealmakers' Intentions 2023

What’s Changed, What’s Changing and What Matters Most Right NowIn this inaugural episode of the limited podcast series on 2023 Health Trends, we’re setting the stage with Host & Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, Leigh Householder. Leigh provides a high-level look at what will be different this year. First, she discusses urgent optimism and the personal, purposeful commitments we have; to take our industry and our world to next. She goes through 12 Health Trends spanning technology, healthcare advancement and human engagement. These trends help us imagine what could be; our next – the future. Listen and learn what’s changed, what’s changing and what matters most right now.Learn more about 2023 Health Trends here. Leigh Householder is the EVP/Managing Director, Technology & Data Science at Syneos Health.   If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!   We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2023 Health Trends: Personally, Purposefully Building What’s Next

When it comes to the generation and use of real-world data (RWD), there are variable and evolving stakeholder needs. Put it in the context of a rare disease, where patient samples are decreasing as diseases splinter with increasing specificity in diagnosis, and the prospect of meeting these stakeholder needs becomes more daunting. Layer on special circumstances—like a required 15 years of post-approval follow-up data for cell and gene therapies (CGT)—and the cards seem to be stacked against you. One way companies can alleviate the burden of RWD generation is through patient registries.Mike D’Ambrosio, VP, Head of Real World Evidence Solutions, Susan Goodlow, VP, RWE and Late Phase Operations and Ray Huml, Head of the Rare Disease Consortium at Syneos Health, discuss the importance of registries for clinical research—particularly for rare disease and CGT, the evolution of rare disease registries and opportunities for the future, and how we can unlock the value of RWD generated from rare disease registries, for all stakeholders.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. Visit our Insights Hub for other content on RWE, rare diseases, and cell and gene therapy.For more episodes on these topics, try:Opportunities and Challenges in Cell and Gene TherapyNavigating the Rare Disease LandscapeReal World Evidence and Rare Diseases, Part 1Real World Evidence and Rare Diseases, Part 2 If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Real World Evidence and Rare Diseases, Part 3: The Value of Registries

Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits—and this is especially true for small or emerging biotechs with limited shots on goal.  But by separating fact from fiction and understanding how to identify fit for purpose solutions, these companies can lay the roadmap for successful implementation of a decentralized clinical trial (DCT) strategy. Stephanie Gonzalez, Senior Vice President and Head of Global Biotech Solutions at Syneos Health and Alison Holland, Executive General Manager for Decentralized Clinical Trials at Medable debunk some common myths and provide an overview of the benefits decentralization can bring to biotechs.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. For more on DCT strategy, check out these insights:3 Capabilities to Achieve Optimal Blend of On-Site and Virtual Patient Engagement in DCTsNot All Decentralized Clinical Trial Capabilities Are Created Equal4 Ways Decentralized Clinical Trials Can Be Game Changers for Better Patient OutcomesHybrid Decentralized Trials in Oncology: A Path to DiversityIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Decentralized Clinical Trials: Implications for Biotech

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. Opportunities for outsourcing some—or all—of a company’s commercial operations can be an option, but many companies have misconceptions about the highly viable “third option” of commercializing with a proven outsourced partner.Lee Taurman, Executive Vice President and Head, Full-Service Commercial and Carl Sailer, Vice President and Global Go-to-Market Lead, both from Syneos Health, discuss the wide range of outsourcing options companies can consider that reduce risk, manage costs and optimize performance while maintaining control of their asset—while debunking some of the myths associated with this alternative path to market.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. For more on commercial options for biotech companies on the verge of market entry, check out these insights:ON-DEMAND WEBINAR: Preparing and Aligning Your Biotech Organization for Commercial SuccessPRESENTATION: Investing for Commercial Success as an Emerging CompanyFive Considerations for Choosing an Agency Partner for a Successful Biopharma LaunchHow Clarity Can Be a Differentiator for Biotechs in Uncertain TimesIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Full-Service Commercial

This podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. Today we are speaking with Dr. Kirk Shepard, co-founder of the Medical Affairs Professional Society (MAPS) and Chief Medical Officer and Head of Global Medical Affairs at Eisai. Dr. Shepard has effectively brought Medical Affairs into the C-Suite, and in this episode we discuss the importance of education, communication, collaboration – and what needs to change as the function continues to advance as a value-based strategic leader.Be sure to listen to the other episodes in this series here. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

MAPS Edition: Bringing Medical Affairs Into the C-Suite

This podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. In this continuation from our previous episode, Colin Oliver, PhD, MBA, Managing Director, Medical Affairs Consulting at Syneos Health, steps in as guest host to dig in more deeply with Eisai’s Dr. Kirk Shepard on a critical question: How do we make the case to our cross-functional partners that Medical Affairs deserves a seat at the leadership table?  And how can we demonstrate the value that Medical Affairs can bring to that table? Be sure to listen to the other episodes in this series here. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

MAPS Edition: Value Demonstration - A View From the Top

Cell and gene therapies have come a long way in the past 20 years. And more recent advances and successes with CRISPR and CAR-T technologies have left the field of opportunity wide open for treatments that can potentially move the needle, particularly for patients with oncologic or rare diseases. But with great advancements come significant challenges.Pete Robinson, Vice President, Medical and Scientific Strategy and Head of the Cell & Gene Therapy Consortium and James Barwick-Silk, Director, Scientific Strategy, Cell & Gene Therapy at Syneos Health discuss the latest exciting developments, as well as hurdles the biopharmaceutical industry must overcome – from R&D, to manufacturing, to access and reimbursement – in order to successfully bring these therapies to market.For more from our experts in rare disease, be sure to check out:Innovation Perspectives in Rare Disease Drug DevelopmentThe Syneos Health Podcast: Navigating the Rare Disease LandscapeThe Syneos Health Podcast: Mental Health in Rare DiseaseThe Syneos Health Podcast: Epilepsy, the Central Nervous System and Rare DiseaseIncorporating the Patient Voice Into the Rare Disease Drug Development ParadigmPrioritizing Mental Health Services for Those Living With Rare DiseaseRare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver PerspectivesIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Opportunities and Challenges in Cell and Gene Therapy

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. As Medical Affairs has evolved, so have the acumen required for Medical Affairs professionals and leaders to succeed. In this episode we sit down with Jackie Tisch, Managing Director, Taylor Strategy Partners, to discuss the new profile of Medical Affairs, how recruiting for these roles has changed and challenges in finding the right fit.Be sure to listen to the other episodes in this series here. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

MAPS Edition: Recruiting for the New Profile of Medical Affairs

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there. There’s been an overall shift in the healthcare ecosystem toward more proactive and cross-functional engagement, altering the fundamental nature of conversations from the perspective of Medical Affairs. In this episode, Anita Holz, Executive Director and Therapeutic Area Head, Cardiometabolism, Clinical Development and Medical Affairs at Boehringer Ingelheim, discusses the evolving interface with healthcare professionals and the power of omnichannel engagement in an increasingly data-driven environment.Be sure to listen to the other episodes in this series here. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

MAPS Edition: Stakeholder Engagement in a Data-Driven Environment

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.It’s no question that Medical Affairs has historically struggled to show value and impact within its organization. In this second episode of the series, Arshi Gupta, Managing Director, Medical Affairs at Syneos Health and Deb Crawford, Director, MSL Team at Teva Pharmaceuticals discuss the intricacies  involved in measuring what seems, well, immeasurable.Be sure to listen to the other episodes in this series here.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

MAPS Edition: Measuring the Immeasurable: Value and Impact of Medical Affairs

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.As a function uniquely positioned to address evolving market dynamics, how can Medical Affairs prepare for 2030 and beyond? In this first episode, hear from Josh Ziel, Executive Vice President, Scientific Services at Syneos Health as he unpacks how we can get beyond incremental improvements to really be bold and think forward as we bring Medical Affairs into the future.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!   We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Get Started

Download the App